At the news
? BULLISHIMPACT 7/10 6-K filed Mar 31, 2026 at 07:48 ET
AstraZeneca announced positive Phase III results for efzimfotase alfa in hypophosphatasia (HPP), with statistically significant and clinically meaningful improvements in bone health in treatment-naïve pediatric patients (MULBERRY trial) and favorable safety and maintained therapeutic benefit in pediatric patients switching from Strensiq (CHESTNUT trial). In adolescents and adults (HICKORY trial), the primary endpoint was not met, though clinically meaningful benefits were observed in prespecified subgroups with pediatric-onset HPP.
- MULBERRY trial met primary endpoint: statistically significant improvement in bone health (RGI-C Score) in treatment-naïve pediatric HPP patients.
- CHESTNUT trial showed efzimfotase alfa was well-tolerated and maintained bone health benefits in pediatric patients switching from Strensiq.
- HICKORY trial did not meet primary endpoint (6MWT) in adolescents/adults, but showed clinically meaningful benefits in mobility, function, and pain reduction in pediatric-onset subgroups.
- Efzimfotase alfa demonstrated a favorable safety profile across all three trials.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access